We are supported by
We don’t bolt a single fix onto a generic cell. The platform integrates manufacturing, navigation and safety so a single engineered cell can reach a solid tumour, get inside, persist, and act — without the toxicity that keeps therapy in the hospital.
Trafficking, infiltration, persistence and safety are usually tackled in isolation. Gaisce treats them as one engineering problem — a single construct whose systems reinforce one another rather than competing for space inside the cell.
Bibac is our non-viral manufacturing system — the vehicle that carries the full engineered package into the cell. Designing for large payload capacity without viral vectors is what makes the rest of the platform possible to build and, eventually, to scale.
Biologic economics, not service economics.
Stayble-T pairs intrinsic durability with autonomous safety. The cell continuously tunes its own TGF-β sensitivity to how intensely it is killing — so the response self-limits without external intervention. That self-regulation is what moves the therapy toward the outpatient setting: the difference between a treatment and an accessible one.
Engineered to be outpatient-ready.
Durability isn’t only about lasting — it’s about thriving where the tumour fights back. The solid-tumour microenvironment switches T-cells off with cytokines like IL-10, IL-4 and TGF-β. Stayble-T’s switch receptors are engineered so those same suppressive signals are read as activating ones — the cell is driven on precisely where others are turned off.
Suppression becomes signal.
Our lead construct, GB-001, is a tumour agnostic asset with first target indication of second-line and later metastatic colorectal cancer. It pairs broad, multi-ligand recognition with a signalling architecture selected for a cleaner tolerability profile than first-generation designs.
We frame these as engineering decisions, not claims — each made against a named failure mode, each carried forward only when the data clears our bar.
We are supported by